Cargando…
Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial
BACKGROUND: The ECHELON-2 5-year update showed continued clinically meaningful improvements in progression-free survival (PFS) and overall survival with frontline (1L) A+CHP (brentuximab vedotin in combination with cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide, doxorubicin, vi...
Autores principales: | Burke, John M, Yu, Kristina S, Mordi, Uche, Bloudek, Brian, Liu, Nicholas, Phillips, Tycel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387925/ https://www.ncbi.nlm.nih.gov/pubmed/36840956 http://dx.doi.org/10.18553/jmcp.2023.29.3.314 |
Ejemplares similares
-
Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology
por: Bloudek, Brian, et al.
Publicado: (2022) -
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy
por: Burke, John M, et al.
Publicado: (2023) -
Value-Based Pricing of US Prescription Drugs: Estimated Savings Using Reports From the Institute for Clinical and Economic Review
por: Yeung, Kai, et al.
Publicado: (2022) -
P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
por: Hutchings, Martin, et al.
Publicado: (2022) -
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
por: Horwitz, S., et al.
Publicado: (2022)